Quantinno Capital Management LP Makes New $315,000 Investment in SELLAS Life Sciences Group, Inc. $SLS

Quantinno Capital Management LP bought a new stake in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 74,378 shares of the company’s stock, valued at approximately $315,000.

Several other large investors have also modified their holdings of the business. Grange Capital LLC grew its stake in shares of SELLAS Life Sciences Group by 18.5% during the fourth quarter. Grange Capital LLC now owns 16,001 shares of the company’s stock valued at $60,000 after buying an additional 2,500 shares during the last quarter. Invesco Ltd. lifted its stake in shares of SELLAS Life Sciences Group by 6.2% during the 4th quarter. Invesco Ltd. now owns 53,293 shares of the company’s stock worth $201,000 after acquiring an additional 3,114 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in SELLAS Life Sciences Group by 13.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 38,018 shares of the company’s stock valued at $143,000 after acquiring an additional 4,564 shares during the period. Equitable Holdings Inc. boosted its holdings in SELLAS Life Sciences Group by 18.5% during the 4th quarter. Equitable Holdings Inc. now owns 32,060 shares of the company’s stock valued at $121,000 after acquiring an additional 5,000 shares during the period. Finally, ProShare Advisors LLC grew its position in SELLAS Life Sciences Group by 31.5% in the 4th quarter. ProShare Advisors LLC now owns 22,638 shares of the company’s stock valued at $85,000 after acquiring an additional 5,417 shares during the last quarter. Hedge funds and other institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Stock Performance

Shares of NASDAQ SLS opened at $15.46 on Monday. The stock has a market capitalization of $3.12 billion, a PE ratio of -73.62 and a beta of 2.48. The stock’s fifty day simple moving average is $11.85 and its two-hundred day simple moving average is $7.75. SELLAS Life Sciences Group, Inc. has a 12-month low of $1.39 and a 12-month high of $15.88.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

Analyst Upgrades and Downgrades

SLS has been the topic of a number of recent analyst reports. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Friday, July 17th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $10.00.

SELLAS Life Sciences Group Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.